Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists dig into immune cells to unlock lung disease mysteries

NCT ID NCT07384897

Knowledge-focused Sponsor: Université Catholique de Louvain Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how immune cells behave in people with lung cancer, sarcoidosis, and COPD. Researchers will collect blood and tissue samples from 425 participants to analyze immune function. No experimental treatments are given. The goal is to understand why some patients don't respond to immunotherapy and to pave the way for better, personalized treatments in the future.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could help scientists develop more personalized and effective treatments for lung cancer and chronic lung diseases.
What could go wrong
This is an observational study, not a treatment trial. It may not directly lead to new therapies, and results may take years to apply.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 425 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2025

Expected to finish

Feb 2032

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Up to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of lung cancer * Presence of precancerous lung lesions * Patients with a chronic inflammatory lung disease (sarcoidosis or chronic obstructive pulmonary disease \[COPD\]) prior to any treatment * Control group: individuals without known lung disease * Children and adolescents weighing ≥ 10 kg with genetically confirmed chronic granulomatous disease (CGD) * Adults scheduled to undergo orthopedic surgery during which a bone marrow sample will be collected Exclusion Criteria: * Systemic corticosteroid therapy \> 10 mg/day prednisone (or equivalent) * Acute infection at the time of inclusion * Refusal or inability to provide informed consent (or assent, when applicable) * Chronic inflammatory lung disease currently treated with immunosuppressive therapy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic granulomatous disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic granulomatous disease chronic obstructive pulmonary disease disease immune system disorder Inflammation lung cancer lung neoplasm non-small cell lung carcinoma sarcoidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic obstructive pulmonary disease Immune dysregulation Immunotherapy resistance Lung cancer (diagnosis) Sarcoidosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Cliniques universitaires saint Luc

    RECRUITING

    Brussels, 1200, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.